Feasibility and Safety of Adoptive Immunotherapy with CIK Cells after Cord Blood Transplantation

Biology of Blood and Marrow Transplantation

Volumn 16, Issue 11, 2010, Pages 1603-1607

  Introna, Martino ^a   Pievani, Alice ^a   Borleri, Gianmaria ^a   Capelli, Chiara ^a   Algarotti, Alessandra ^a   Micò, Caterina ^a   Grassi, Anna ^a   Oldani, Elena ^a   Golay, Josée ^a   Rambaldi, Alessandro ^a  

^a Ospedali Riuniti Bergamo   (Italy)

Author keywords

Cell therapy; Cord blood transplantation; Cytokine induced killer (CIK) cells; GVHD; Mesenchymal stromal cells; Relapse

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; DOXORUBICIN; FLUDARABINE; MELPHALAN; METHOTREXATE; RECOMBINANT INTERLEUKIN 2; THIOTEPA; THYMOCYTE ANTIBODY; TREOSULFAN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOPTIVE IMMUNOTHERAPY; ADULT; ARTICLE; CANCER RELAPSE; CELL CULTURE; CLINICAL ARTICLE; CORD BLOOD STEM CELL TRANSPLANTATION; CYTOKINE INDUCED KILLER CELL; EX VIVO STUDY; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; MALE; SINGLE DRUG DOSE; TREATMENT RESPONSE;

ADOLESCENT; ADULT; CORD BLOOD STEM CELL TRANSPLANTATION; CYTOKINE-INDUCED KILLER CELLS; CYTOTOXICITY TESTS, IMMUNOLOGIC; FEMALE; FETAL BLOOD; GRAFT VS HOST DISEASE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; K562 CELLS; LEUKEMIA; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MIDDLE AGED; RECURRENCE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 77957749135     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2010.05.015     Document Type: Article

References (14)

1. Smith A.R., Wagner J.E. Alternative haematopoietic stem cell sources for transplantation: place of umbilical cord blood. Br J Haematol 2009, 147:246.
2. Rocha V., Labopin M., Sanz G., et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med 2004, 351:2276.
3. Eapen M., Rubinstein P., Zhang M.J., et al. Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study. Lancet 2007, 369:1947.
4. Kamani N., Spellman S., Hurley C.K., et al. State of the art review: HLA matching and outcome of unrelated donor umbilical cord blood transplants. Biol Blood Marrow Transplant 2008, 14:1.
5. Introna M., Franceschetti M., Ciocca A., et al. Rapid and massive expansion of cord blood-derived cytokine-induced killer cells: an innovative proposal for the treatment of leukemia relapse after cord blood transplantation. Bone Marrow Transplant 2006, 38:621.
6. Franceschetti M., Pievani A., Borleri G., et al. Cytokine-induced killer cells are terminally differentiated activated CD8 cytotoxic T-EMRA lymphocytes. Exp Hematol 2009, 37:616.
7. Nishimura R., Baker J., Beilhack A., et al. In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity. Blood 2008, 112:2563.
8. Thorne S.H., Negrin R.S., Contag C.H. Synergistic antitumor effects of immune cell-viral biotherapy. Science 2006, 311:1780.
9. Introna M., Borleri G., Conti E., et al. Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study. Haematologica 2007, 92:952.
10. Falini B., Mecucci C., Tiacci E., et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005, 352:254.
11. Gorello P., Cazzaniga G., Alberti F., et al. Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations. Leukemia 2006, 20:1103.
12. Le Blanc K., Rasmusson I., Sundberg B., et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004, 363:1439.
13. Le Blanc K., Frassoni F., Ball L., et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008, 371:1579.
14. Baker J., Verneris M.R., Ito m, et al. Expansion of cytolytic CD8(+) natural killer T cells with limited capacity for graft-versus-host disease induction because of interferon gamma production. Blood 2001, 97:2923.